posted by Alliance Family of Companies
on December 6, 2019
Epilepsy is a neurological disease characterized by recurring, unprovoked seizures, with diagnosis typically occurring after 2 such seizures . Common etiologies of epilepsy include stroke, infections of the central nervous system, metabolic disturbances, brain tumors, encephalomalacia with gliosis, and cortical venous thrombosis . In 2015, the Centers for Disease Control and Prevention estimated that 1.2% of the United States (US) population had active epilepsy, representing 3.4 million people nationwide . Approximately 1 in 26 people will develop epilepsy over the course of their lifetime .
Epilepsy is associated with considerable economic and humanistic burden. The total direct cost of epilepsy in the US is estimated to be $15.5 billion annually . A review of studies published since 1995 found that annual per-person, epilepsy-specific costs (in 2013 dollars) ranged from $1,022 to $19,749 . This same review found that these estimates were supported by claims-based studies conducted more recently that used more comparable methods for cost estimation, showing similar annual epilepsy cost estimates that ranged from $8,412 to $11,354 . Additionally, studies have consistently shown that annual, epilepsy-specific direct costs are higher for uncontrolled or treatment-refractory epilepsy vs controlled or treatment-responsive epilepsy [5–9].